



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2024/031768

(22) International Filing Date:
30 May 2024 (30.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/469,766 30 May 2023 (30.05.2023) US
63/578,838 25 August 2023 (25.08.2023) US

(71) Applicant: **ASKLEPIOS BIOPHARMACEUTICAL, INC.** [US/US]; 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US).

(72) Inventors: **MOULLIER, Philippe**; c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **GABRIEL, Sherif**; c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **DEACON, Patrick**; c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina

27709 (US). **BOERNER, Kathleen**; c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US).

(74) Agent: **YOUNG, Alissa R.** et al.; Nixon Peabody LLP, 53 State Street, Exchange Place, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: METHODS OF RECOMBINANT ADENO-ASSOCIATED VIRUS KIDNEY ADMINISTRATION

(57) Abstract: The technology described herein is directed to methods of administering a recombinant adeno-associated virus (rAAV) to a kidney of a subject using a retrograde ureter route. Such administration methods can be used to treat a kidney-associated disorder in a subject in need thereof. Also described herein are pharmaceutical compositions comprising a recombinant adeno-associated virus (rAAV) for administration to the kidney.




Fig. 7J

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*